Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Maravai LifeSciences (MRVI) stock in plain English

Free brief · no signupStart here
MRVIPublished Nov 19, 2026
Maravai LifeSciences Holdings Inc
Healthcare · Biotechnology
Manufactures specialized nucleic acids, mRNA capping reagents, and purity testing kits for biopharmaceutical developers.
Assets:
CleanCap technologyPatented co-transcriptional capping analog for mRNA therapies
San Diego facilitiesTwo commercial-scale nucleic acid manufacturing sites in California
Cygnus TechnologiesSpecialized analytical kits detecting host cell protein impurities
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

46
OPS ScoreOperating finances
Latest quote
-2.57%$7.19
$1.87B
n/a (loss)
$213.11M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MRVI. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Maravai LifeSciences (MRVI) do?

Maravai LifeSciences Holdings Inc (MRVI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Manufactures specialized nucleic acids, mRNA capping reagents, and purity testing kits for biopharmaceutical developers. It manufactures chemical capping reagents and analytical test kits required to produce and purify mRNA medicines. It is worth $1.87B on the market and sold $213.11M over the last year.

Market cap
$1.87B
P/E ratio
None (reported a loss)
Annual sales
$213.11M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind MRVI

  • TriLink BioTechnologies: It manufactures custom nucleic acids and mRNA capping reagents, earning revenue from research and clinical biopharma contracts.
  • Cygnus Technologies: It develops and sells assay kits that measure host cell protein impurities during biologic drug manufacturing.
  • Glen Research: It supplies chemical reagents and synthesis tools used to create specialized DNA and RNA oligonucleotides.
  • Alphazyme: It develops custom enzyme formulations sold to diagnostic developers and therapeutic nucleic acid producers.

MRVI’s flags, in plain English

Each flag is a number from Maravai LifeSciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 25.3% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -30.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about MRVI

How big is Maravai LifeSciences?

Maravai LifeSciences’ market cap is $1.87B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $213.11M: what customers paid the company over the last year, before any costs.

What is MRVI’s P/E ratio?

MRVI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with MRVI?

Sales have dropped significantly as commercial demand for pandemic-related mRNA vaccines fell sharply from previous highs. That is one risk on Maravai LifeSciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Maravai LifeSciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRVI’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card